Fig. 5.
The effect of increasing doses of coagulation factor concentrate (CFC) on human platelet-poor plasma anticoagulated with different concentrations of dabigatran; (A) Beriplex, (B) NovoSeven, (C) Octaplex, (D) Factor Eight Inhibitor Bypassing Activity (FEIBA), (E) Profilnine, and (F) Bebulin. Data represent mean ± SEM (n = 5 per group); endogenous thrombin potential (ETP; area under the thrombin-time integral, nM × min). *P < 0.05 versus control (untreated plasma), dotted line. †P < 0.05 versus dabigatran 200 ng/ml, no CFC. ‡P < 0.05 versus dabigatran 600 ng/ml, no CFC. §P < 0.05 versus dabigatran 1,000 ng/ml, no CFC. Bebulin (Baxter BioScience, Westlake Village, CA); Beriplex (CSL Behring, Marburg, Germany); FEIBA (Baxter AG, Vienna, Austria); NovoSeven (NovoNordisk, Bagsværd, Denmark); Octaplex (Octapharma AG, Lachen, Switzerland); Profilnine (Grifols Biologicals Inc., Los Angeles, CA).

The effect of increasing doses of coagulation factor concentrate (CFC) on human platelet-poor plasma anticoagulated with different concentrations of dabigatran; (A) Beriplex, (B) NovoSeven, (C) Octaplex, (D) Factor Eight Inhibitor Bypassing Activity (FEIBA), (E) Profilnine, and (F) Bebulin. Data represent mean ± SEM (n = 5 per group); endogenous thrombin potential (ETP; area under the thrombin-time integral, nM × min). *P < 0.05 versus control (untreated plasma), dotted line. †P < 0.05 versus dabigatran 200 ng/ml, no CFC. ‡P < 0.05 versus dabigatran 600 ng/ml, no CFC. §P < 0.05 versus dabigatran 1,000 ng/ml, no CFC. Bebulin (Baxter BioScience, Westlake Village, CA); Beriplex (CSL Behring, Marburg, Germany); FEIBA (Baxter AG, Vienna, Austria); NovoSeven (NovoNordisk, Bagsværd, Denmark); Octaplex (Octapharma AG, Lachen, Switzerland); Profilnine (Grifols Biologicals Inc., Los Angeles, CA).

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal